S&P 500   3,273.74 (+0.84%)
DOW   26,964.78 (+0.56%)
QQQ   268.72 (+1.25%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
S&P 500   3,273.74 (+0.84%)
DOW   26,964.78 (+0.56%)
QQQ   268.72 (+1.25%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
S&P 500   3,273.74 (+0.84%)
DOW   26,964.78 (+0.56%)
QQQ   268.72 (+1.25%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
S&P 500   3,273.74 (+0.84%)
DOW   26,964.78 (+0.56%)
QQQ   268.72 (+1.25%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
Log in
NASDAQ:ITOS

Pandion Therapeutics Holdco Stock Forecast, Price & News

$24.30
+2.47 (+11.31 %)
(As of 09/25/2020 12:27 PM ET)
Add
Compare
Today's Range
$22.41
Now: $24.30
$24.33
50-Day Range N/A
52-Week Range
$17.50
Now: $24.30
$34.33
Volume4,635 shs
Average Volume238,402 shs
Market Capitalization$851.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITOS
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees43
Market Cap$851.59 million
Next Earnings DateN/A
OptionableNot Optionable
$24.30
+2.47 (+11.31 %)
(As of 09/25/2020 12:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ITOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pandion Therapeutics Holdco (NASDAQ:ITOS) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pandion Therapeutics Holdco?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pandion Therapeutics Holdco in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pandion Therapeutics Holdco
.

What price target have analysts set for ITOS?

4 analysts have issued 1-year target prices for Pandion Therapeutics Holdco's stock. Their forecasts range from $36.00 to $50.00. On average, they expect Pandion Therapeutics Holdco's stock price to reach $42.75 in the next twelve months. This suggests a possible upside of 75.9% from the stock's current price.
View analysts' price targets for Pandion Therapeutics Holdco
.

Who are some of Pandion Therapeutics Holdco's key competitors?

What other stocks do shareholders of Pandion Therapeutics Holdco own?

Who are Pandion Therapeutics Holdco's key executives?

Pandion Therapeutics Holdco's management team includes the following people:
  • Dr. Michel Detheux, CEO & Director (Age 54, Pay $978.95k)
  • Mr. Matthew A. Call M.B.A., Chief Operating Officer (Age 47, Pay $206.4k)
  • Dr. Joanne Jenkins Lager M.D., Chief Medical Officer (Age 49, Pay $482.38k)
  • Mr. Matthew Gall, Chief Financial Officer (Age 43)

When did Pandion Therapeutics Holdco IPO?

(ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Pandion Therapeutics Holdco's stock symbol?

Pandion Therapeutics Holdco trades on the NASDAQ under the ticker symbol "ITOS."

When did Pandion Therapeutics Holdco's quiet period expire?

Pandion Therapeutics Holdco's quiet period expired on Wednesday, September 2nd. Pandion Therapeutics Holdco had issued 10,586,316 shares in its initial public offering on July 24th. The total size of the offering was $201,140,004 based on an initial share price of $19.00. During Pandion Therapeutics Holdco's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Pandion Therapeutics Holdco?

Shares of ITOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pandion Therapeutics Holdco's stock price today?

One share of ITOS stock can currently be purchased for approximately $24.30.

How big of a company is Pandion Therapeutics Holdco?

Pandion Therapeutics Holdco has a market capitalization of $851.59 million. Pandion Therapeutics Holdco employs 43 workers across the globe.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.